Sriwidyani Ni Putu, Adiputra Putu Anda Tusta, Sudarsa I Wayan, Suega Ketut
Department of Pathology, Udayana University, Prof. I.G.N.G Ngoerah General Hospital, Badung, Bali, Indonesia.
Department of Surgical Oncology, Udayana University, Prof. I.G.N.G Ngoerah General Hospital, Badung, Bali, Indonesia.
Asian Pac J Cancer Prev. 2025 Jan 1;26(1):117-126. doi: 10.31557/APJCP.2025.26.1.117.
To explore the significance of diminished CD3/CD8 and CD3/CDR45RO immunoscores, as well as elevated FOXP3 expression, as potential risk factors for unfavorable responses to neoadjuvant chemotherapy among patients with triple-negative breast cancer (TNBC).
A case-control study was conducted across two hospitals (a public and a private facility) from August 1st, 2021, to August 31st, 2022. The study population comprised patients diagnosed with the TNBC subtype, with available paraffin blocks from biopsy procedures. Immunohistochemical staining was performed on specimens for CD3, CD8, CD45RO, and FOXP3 antibodies.
A total of seventy-two patients were enrolled in the study, among whom seven patients (16.7%) achieved a pathological complete response to neoadjuvant chemotherapy (NAC). Notably, there existed a significant correlation between CD3/CD8 and CD3/CD45RO immunoscores, as well as FOXP3 expression, and NAC response (p<0.05). Multivariate analysis involving 70 samples from the case-control study revealed that a diminished CD3/CD8 immunoscore (aOR=10.930; 95% CI=1.336-89.420) and heightened FOXP3 expression (aOR=11.775; 95% CI =2.537-54.656) independently posed as risk factors for unfavorable NAC response (p<0.05). However, the CD3/CD45RO immunoscore did not emerge as an independent risk factor for NAC response.
A reduced CD3/CD8 immunoscore and elevated FOXP3 expression stand as autonomous risk factors for suboptimal NAC response in patients with TNBC.
探讨CD3/CD8和CD3/CD45RO免疫评分降低以及FOXP3表达升高作为三阴性乳腺癌（TNBC）患者新辅助化疗不良反应潜在危险因素的意义。
于2021年8月1日至2022年8月31日在两家医院（一家公立医院和一家私立医院）开展一项病例对照研究。研究人群包括诊断为TNBC亚型且有活检石蜡块的患者。对标本进行CD3、CD8、CD45RO和FOXP3抗体的免疫组织化学染色。
共有72例患者纳入研究，其中7例（16.7%）新辅助化疗（NAC）后达到病理完全缓解。值得注意的是，CD3/CD8和CD3/CD45RO免疫评分以及FOXP3表达与NAC反应之间存在显著相关性（p<0.05）。对病例对照研究中的70个样本进行多因素分析显示，CD3/CD8免疫评分降低（aOR=10.930；95%CI=1.336 - 89.420）和FOXP3表达升高（aOR=11.775；95%CI =2.537 - 54.656）独立构成NAC不良反应的危险因素（p<0.05）。然而，CD3/CD45RO免疫评分并未成为NAC反应的独立危险因素。
CD3/CD8免疫评分降低和FOXP3表达升高是TNBC患者NAC反应欠佳的独立危险因素。
